New hope for Tough-to-Treat blood cancer: experimental injection takes on standard therapy
NCT ID NCT07452198
Summary
This study is testing whether a new injection called GR1803 works better than the current standard treatment for multiple myeloma that has returned or stopped responding to previous therapies. It will involve about 358 adults whose cancer has progressed after 1-3 prior treatments that included specific medications. Researchers will randomly assign participants to receive either the new injection or the standard three-drug combination to compare how long the cancer stays under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.